Overview

Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine

Status:
Withdrawn

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety of 2 fixed doses of EVP-6124 hydrochloride (HCl) compared to placebo for 24 weeks in subjects with mild to moderate Alzheimer's disease who are concurrently receiving stable treatment with memantine and currently receiving stable treatment or previously treated with an acetylcholinesterase inhibitor.

Phase:

Phase 2

Details

Lead Sponsor:

FORUM Pharmaceuticals Inc

Collaborator:

Quintiles, Inc.

Treatments:

Cholinesterase Inhibitors
Memantine